Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to determine whether pharmaco(epi)genetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Who May Be Eligible (Plain English)

Who May Qualify: 1. age 19\~ 70 2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV) 3. drug naive or drug free for more than 3 months Who Should NOT Join This Trial: 1. any neurological disorder 2. comorbid psychotic disorders 3. alcohol or other substance dependence within past 6 months 4. any evidences for brain diseases Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. age 19\~ 70 2. OCD by Diagnostic and Statistical Manual for Mental disorders, 4th edition (DSM-IV) 3. drug naive or drug free for more than 3 months Exclusion Criteria: 1. any neurological disorder 2. comorbid psychotic disorders 3. alcohol or other substance dependence within past 6 months 4. any evidences for brain diseases

Treatments Being Tested

DRUG

SSRIs

usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents

Locations (1)

Yonsei Univ. Health System Severance Hospital
Seoul, South Korea